A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil

Anticancer Research

Volumn 22, Issue 6 B, 2002, Pages 3621-3627

  Hsu, Chih Hung ^b   Cheng, Ann Lii ^b   Hsu, Chiun ^b   Yang, Chih Hsin ^b   Lu, Yen Shen ^b   Lin, Chia Chi ^b   Bu, Ching Fang ^b   Yeh, Kun Huei ^a  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

Chemotherapy; Cisplatin; Esophageal cancer; Infusional 5 FU; Methotrexate

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; METHOTREXATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG POTENTIATION; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SEPSIS; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES;

EID: 0036875569     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Roth JA and Putnam JB Jr: Surgery for cancer of the esophagus. Semin Oncol 21: 453-461, 1994.
2. th ed. (DeVita VT, Jr, Hellman S and Rosenberg SA, eds). Philadelphia, Lippincott Williams & Wilkins, 2001, pp 1051-91.
3. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L and Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. New Engl J Med 326: 1593-1598, 1992.
4. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr., Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV and Leichman LL: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281: 1623-1627, 1990.
5. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N and Hennessy TP: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. New Engl J Med 335: 462-467, 1996.
6. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M and Sahmoud T: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. New Engl J Med 337: 161-167, 1997.
7. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A and Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19: 305-313, 2001.
8. Minsky BD, Berkey B, Kelsen DK, Ginsberg R, Pisansky T, Martenson J, Komaki R, Okawara G and Rosenberg S: Preliminary results of Intergroup INT 0123 randomized trial of combined modality therapy (CMT) for esophageal cancer: standard vs. high dose radiation therapy. Proc Am Soc Clin Oncol 19: Abstr 927, 2000.
9. Enzinger PC, Ilson DH and Kelson DP: Chemotherapy in esophageal cancer. Semin Oncol 26(5, Suppl 15): 12-20, 1999.
10. Kok TC: Chemotherapy in esophageal cancer: a review. Cancer Treat Rev 23: 65-85, 1997.
11. Lokich JJ, Anderson N, Bern M, Coco F and Dow E: The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen. Cancer 85: 499-503, 1999.
12. Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto P, Richman S, Legaspi A, Waldman S and Morrell L: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9: 625-630, 1991.
13. Cheng AL, Yeh KH, Lin JT, Hsu C and Liu MY: Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL) - a very effective regimen with good patients' compliance for advanced gastric cancer. Anticancer Res 18: 1267-1272, 1998.
14. Yeh KH, Cheng AL, Lin MT, Hong RL, Hsu CH, Lin JF, Chang KJ, Lee PH and Chen YC: A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers. Anticancer Res 17: 3867-3871, 1997.
15. Hsu CH, Yeh KH, Chen LT, Liu JM, Jan CM, Lin JT, Chen YC and Cheng AL: Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers. An effective and low-toxic regimen for patients with poor general condition. Oncology 54: 275-280, 1997.
16. Chi KH, Chan WK, Shu CH, Law CK, Chen SY, Yen SH and Chen KY: Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. Cancer 76: 2186-2192, 1995.
17. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
18. Yeh KH, Cheng AL, Chen YC, Lin MT, Hong RL and Hsieh CY: Unusual neurotoxicity during 24-hour infusion of high-dose 5-fluorouracil and folinic acid in malnourished hypotriglyceridemic cancer patients. Proc Am Soc Clin Oncol 14: 167 (Abstract), 1995.
19. Yeh KH and Cheng AL: High-dose 5-fluorouracil infusional therapy is associated with hyperammonemia, lactic acidosis, and encephalopathy. Br J Cancer 75: 464-465, 1997.
20. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
21. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L and Sahmoud T: Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33: 1216-1220, 1997.
22. Levard H, Pouliquen X, Hay JM, Fingerhut A, Langlois-Zantain O, Huguier M, Lozach P and Testart J: 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research. Eur J Surg 164: 849-857, 1998.
23. Sotos GA, Grogan L and Allegra CJ: Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev 20: 11-49, 1994.
24. Grem JL: 5-Fluoropyrimidines. In: Cancer Chemotherapy and Biotherapy, 2nd ed. (Chabner BA and Longo DL,eds). Philadelphia, Lippincott-Raven Publishers. 1996, pp 149-211.
25. Poon MA, O'Connel MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK and Wiesenfeld M: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinomas. J Clin Oncol 7: 1407-1417, 1989.
26. Petrelli N, Douglass HD Jr, Herrerd L, Russell D, Stablein DM, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM, Megibow A, Greenwaild ES, Bukowski RM, Harris J, Levin B, Gaynor E, Loutfi A and Leichman LP for the Gastrointestinal Tumor Study Group: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7: 1419-1426, 1989.
27. Advanced Colorectal Cancer Meta-analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10: 876-903, 1992
28. Kohne CH, Schoffski P, Wilke H, Kaufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstick A, Bade J, Horster A, Schubert U, Hecker H, Dorken B and Schmoll HJ: Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 16: 418-426, 1998.
29. Marsh JC, Bertino JR, Katz KH, Devis CA, Durivage HJ, Rome LS, Richards II F, Capizzi RL, Farber LR, Pasquale DN, Stuart R, Koletsky AJ, Makuch R and O'Hollaren K: The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 9: 371-380, 1991.
30. The Nodic Gastrointestinal Tumor Adjuvant Therapy Group: Superiority of sequential methotrexate, fluorouracil and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial. J Clin Oncol 7: 1437-1446, 1989.
31. Machiavelli M, Leone BA, Romero A, Rabinovich MG, Vallejo CT, Bianco A, Perez JE, Rodriguez R, Cuevas MA and Alvarez LA: Advanced colorectal carcinoma. A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone. Am J Clin Oncol 14: 211-217, 1991.
32. Chu E and Allegra CJ: Antifolates. In: Cancer Chemotherapy and Biotherapy, 2nd ed. (Chabner BA and Longo DL,eds). Philadelphia, Lippincott-Raven Publishers. 1996, pp 109-148.
33. Esaki T, Nakano S, Tatsumoto T, Kuroki-Migita M, Mitsugi K, Nakamura M and Niho Y: Inhibition by 5-fluorouracil of cisdiamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line. Cancer Res 52: 6501-6506, 1992.
34. Kuroki M, Nakano S, Mitsugi K, Ichinose I, Anzai K, Nakamura M, Nagafuchis and Niho Y: In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamous-carcinoma cell line. Cancer Chemother Pharmacol 29: 273-276, 1992.
35. Vokes EE, Moran WJ, Mick R, Weichselbaum RR and Panje WR: Neoadjuvant and adjuvant methotrexate, cisplatin, and fluorouracil in multimodal therapy of head and neck cancer. J Clin Oncol 7: 838-845, 1989.
36. Lynch TJ, Clark JR, Kalish LA, Fallon BG, Elias AD, Skarin A and Frei E 3rd: Continuous-infusion cisplatin, 5-fluorouracil, and bolus methotrexate in the treatment of advanced non-small cell lung cancer. Cancer 70: 1880-1885, 1992.
37. Conte PF, Sertoli MR, Bruzzone M, Rubagotti A, Rosso R, Bentivoglio G, Conio A and Pescetto G: Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer. Gynecol Oncol 20: 290-297, 1985.
38. Di Costanzo F, Canaletti R, Sdrobolini A, Olmeo N, Luppi G, Pucci F, Cavicchi F, Gasperoni S, Rodino C, Zironi S, Angiona S and Contu A: Modulation of fluorouracil by methotrexate, leucovorin, and cisplatin (M-FLP) in the treatment of advanced pancreatic cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC). Am J Clin Oncol 23: 314-318, 2000.
39. Oh WK, Manola J, Richie JP, Loughlin KR and Kantoff PW: A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. Cancer 86: 1329-1334, 1999.
40. Caponigro F, Comella P, Marcolin P, Russo Spena F, Biglietto M, Carteni G, De Lucia L, Avallone A, Gravina A and Comella G: A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck. Cancer 85: 952-959, 1999.
41. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM and Kelsen DP: Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86: 1086-1091, 1994.
42. Conroy T, Etienne PL, Adenis A, Wagener DJ, Paillot B, Francois E, Bedenne L, Jacob JH, Seitz JF, Bleiberg H, Van Pottelsberghe C, Van Glabbeke M, Delgado FM, Merle S and Wils J: Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J Clin Oncol 14: 164-170, 1996.
43. Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, O'Reilly E, Schwartz G, DeGroff J, Gonzalez G and Kelsen DP: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17: 3270-3275, 1999.